

## **Financial Transparency** <sup>[1]</sup>

### **Healthcare professional engagement in Australia**

The new Medicines Australia Code of Conduct will increase transparency about the vital role of healthcare professionals in the development and use of new, innovative medicines. Healthcare professionals help to educate patients about medicines and their safe, ongoing use – a bond of trust that we, as a Medicines Australia member company, want to help make even stronger.

Novartis values the expert knowledge of patient behavior and of management of diseases that comes from interactions with the healthcare community, and from 31 August 2016, Novartis Pharmaceuticals and Alcon, will disclose details of these engagements on this site. Novartis and Alcon Laboratories (Australia) Pty Ltd (a Novartis company) will provide details of reportable payments or transfers of value to a healthcare professional.

Reportable payments or transfers of value are:

- Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant
- Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.

The reports are downloadable below, and these will be available for at least 3 years from the date of publication.

These reports can also now be found on the Medicines Australia Centralised Reporting System [here](#) <sup>[2]</sup>.

#### **Latest Report**

[Novartis Pharmaceuticals - 1 May 2019 to 31 October 2019 \(PDF 616KB\)](#) <sup>[3]</sup> [\(CSV 175KB\)](#) <sup>[4]</sup>

#### **Previous Reports**

[Novartis Pharmaceuticals - 31 October 2018 to 30 April 2019 \(PDF 298KB\)](#) <sup>[5]</sup> <sup>[6]</sup> [\(CSV 86KB\)](#) <sup>[7]</sup>

[Novartis Pharmaceuticals - 1 May 2018 to 31 October 2018 \(PDF 417KB\)](#) <sup>[8]</sup> [\(CSV 122KB\)](#) <sup>[9]</sup>

[Novartis Pharmaceuticals - 1 November 2017 to 30 April 2018 \(PDF 136KB\)](#) <sup>[10]</sup> [\(CSV 87KB\)](#)  
<sup>[10]</sup>

[Novartis Pharmaceuticals - 1 May 2017 to 31 October 2017 \(PDF 917KB\)](#) <sup>[11]</sup> <sup>[12]</sup> <sup>[11]</sup>[\(CSV 185KB\)](#) <sup>[9]</sup>

[Novartis Pharmaceuticals - 1 November 2016 to 30 April 2017 \(PDF 548KB\)](#) <sup>[13]</sup> [\(CSV 1144KB\)](#)  
<sup>[14]</sup>

\*Alcon is no longer required to report due to 2016 transfer of the Ophthalmic Pharmaceuticals franchise from the Alcon Division to the Novartis Pharmaceuticals Division

[Alcon - 1 May 2016 to 31 October 2016 \(PDF 237KB\)](#) <sup>[15]</sup> [\(CSV 3KB\)](#) <sup>[16]</sup>

[Novartis Pharmaceuticals - 1 May 2016 to 31 October 2016 \(PDF 188KB\)](#) <sup>[17]</sup> [\(CSV 144KB\)](#) <sup>[18]</sup>

[Alcon - 1 October 2015 to 30 April 2016 \(PDF 217KB\)](#) ( <sup>[19]</sup>[CSV 711 bytes](#) <sup>[20]</sup> ) <sup>[19]</sup>

[Novartis Pharmaceuticals - 1 October 2015 to 30 April 2016 \(PDF 187KB\)](#) <sup>[21]</sup> [\(CSV 67KB\)](#) <sup>[22]</sup>

To comply with our privacy obligations, the report may be amended from time to time. The reports here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the Australian Privacy Act 1988.

For further information about the details in the report, please visit

[www.medicinesaustralia.com.au](http://www.medicinesaustralia.com.au) <sup>[23]</sup>

For access to Novartis's Privacy Policy please [click here](#) <sup>[24]</sup>. For access to Alcon's Privacy Policy or further information, please contact [privacy.australia@alcon.com](mailto:privacy.australia@alcon.com) <sup>[25]</sup>.

We believe that greater transparency will increase confidence by patients that the working relationship between the industry and healthcare professionals is ethical and appropriate.

## **Accordion Type:**

Collapsible

---

**Source URL:** <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia/financial-transparency>

## **Links**

[1] <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia/financial-transparency>

[2] <https://www.disclosureaustralia.com.au/>

[3]

[https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis\\_HCP%20Payment%20and%20ToV\\_201905020191031%20May%20to%20October.pdf](https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis_HCP%20Payment%20and%20ToV_201905020191031%20May%20to%20October.pdf)

[4]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/May%20to%20October%202019%20HCP%20CSV.csv>

[5]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/documents/Copy%20of%20Novartis%20Pharmaceutica>

[6]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Financial%20transparency%20April%2030.xlsx>

[7]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Financial%20transparency%20April%20CSV.csv>

[8]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/May18%20to%20Oct18%20Novartis%20Pharmaceutic>

[9]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/May18%20to%20Oct18%20Novartis%20Pharmaceutic>

[10]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis%20Pharmaceutical%20Australia%20Pty%20L>

[11]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis%20Pharmaceutical%20Australia%20Pty%20L>

[12]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis%20Pharmaceutical%20Australia%20Pty%20L>

[13]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis%20Pharmaceutical%20Australia%20Pty%20L>

[14]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis%20Pharmaceutical%20Australia%20Pty%20L>

[15] [https://www.novartis.com.au/sites/www.novartis.com.au/files/FINAL\\_MA-E18-HCP-ToV\\_2016.pdf](https://www.novartis.com.au/sites/www.novartis.com.au/files/FINAL_MA-E18-HCP-ToV_2016.pdf)

[16] [https://www.novartis.com.au/sites/www.novartis.com.au/files/FINAL\\_MA-E18-HCP-ToV\\_2016.csv](https://www.novartis.com.au/sites/www.novartis.com.au/files/FINAL_MA-E18-HCP-ToV_2016.csv)

[17]

<https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis%20Pharmaceutical%20Australia%20Pty%20L>

[18]

[https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis\\_HCP%20Payment%20and%20ToV\\_1%20Ma](https://www.novartis.com.au/sites/www.novartis.com.au/files/Novartis_HCP%20Payment%20and%20ToV_1%20Ma)

[19] <https://www.novartis.com.au/sites/www.novartis.com.au/files/MA-E18-HCP->

[ToV\\_31%20August%202016\\_Alcon.pdf](https://www.novartis.com.au/sites/www.novartis.com.au/files/MA-E18-HCP-ToV_31%20August%202016_Alcon.pdf)

[20] <https://www.novartis.com.au/sites/www.novartis.com.au/files/MA-E18-HCP->

[ToV\\_31%20August%202016\\_Alcon%20CSV.csv](https://www.novartis.com.au/sites/www.novartis.com.au/files/MA-E18-HCP-ToV_31%20August%202016_Alcon%20CSV.csv)

[21] <https://www.novartis.com.au/sites/www.novartis.com.au/files/OCT%202015%20->

[%20APR%202016\\_Novartis%20Pharmaceuticals\\_HCP%20Payments%20and%20ToV.pdf](https://www.novartis.com.au/sites/www.novartis.com.au/files/OCT%202015%20-%20APR%202016_Novartis%20Pharmaceuticals_HCP%20Payments%20and%20ToV.pdf)

[22] <https://www.novartis.com.au/sites/www.novartis.com.au/files/OCT%202015%20->

[%20APR%202016\\_Novartis%20Pharmaceuticals\\_HCP%20Payments%20and%20ToV%20CSV.csv](https://www.novartis.com.au/sites/www.novartis.com.au/files/OCT%202015%20-%20APR%202016_Novartis%20Pharmaceuticals_HCP%20Payments%20and%20ToV%20CSV.csv)

[23] <http://www.medicinesaustralia.com.au>

[24] <https://www.novartis.com.au/privacy-policy>

[25] <mailto:privacy.australia@alcon.com>